Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers

G. Corrado, V. Laquintana, R. Loria, M. Carosi, L. de Salvo, I. Sperduti, A. Zampa, L. Cicchillitti, G. Piaggio, G. Cutillo, R. Falcioni, E. Vizza

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Patients with endometrial cancer (EC) and presumably with good prognosis may develop a recurrence indicating that the classification of this tumor is still not definitive and that new markers are needed to identify a subgroup at risk of relapse. The cell adhesion molecule L1CAM is highly expressed in several human carcinomas and has recently been described as a new marker for endometrial and ovarian carcinomas. The aim of this study was to determine the relevance of L1CAM in recurrent EC. METHODS: In this work we have analyzed, by immunohistochemical and RT-qPCR analysis, the expression of L1CAM in a cohort of 113 endometrial cancers at different stages, which 50% have relapsed. As a predictor of good outcome, the tumors were also analyzed for the expression of miR-34a, a post-transcriptional regulator of L1CAM. RESULTS: Among metastatic EC, the highest levels (60%) and the median level (24%) of L1CAM in tumors correlate with the progression, suggesting that the expression of this molecule is linked to the tumor component most involved in metastatic processes. We also found an inverse correlation between miR-34a and L1CAM protein expression, suggesting that miR-34a is a positive prognostic marker of EC. CONCLUSIONS: Our results demonstrate the expression of L1CAM and miR-34a in EC as prognostic factors that identify subgroup of patients at high risk of recurrence suggesting for them more aggressive schedules of treatment.
Original languageEnglish
Pages (from-to)139
JournalJournal of experimental & clinical cancer research : CR
Volume37
Issue number1
DOIs
Publication statusPublished - Jul 6 2018

Fingerprint

Neural Cell Adhesion Molecule L1
Endometrial Neoplasms
Biomarkers
Recurrence
Neoplasms
Cell Adhesion Molecules
Appointments and Schedules
Carcinoma

Keywords

  • Endometrial cancer
  • Innovative biotechnology
  • L1CAM
  • Personalised approach
  • Prognostic biomarker

Cite this

Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers. / Corrado, G.; Laquintana, V.; Loria, R.; Carosi, M.; Salvo, L. de; Sperduti, I.; Zampa, A.; Cicchillitti, L.; Piaggio, G.; Cutillo, G.; Falcioni, R.; Vizza, E.

In: Journal of experimental & clinical cancer research : CR, Vol. 37, No. 1, 06.07.2018, p. 139.

Research output: Contribution to journalArticle

@article{7f631f4c4b46417195bbf4ddee9d4775,
title = "Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers",
abstract = "BACKGROUND: Patients with endometrial cancer (EC) and presumably with good prognosis may develop a recurrence indicating that the classification of this tumor is still not definitive and that new markers are needed to identify a subgroup at risk of relapse. The cell adhesion molecule L1CAM is highly expressed in several human carcinomas and has recently been described as a new marker for endometrial and ovarian carcinomas. The aim of this study was to determine the relevance of L1CAM in recurrent EC. METHODS: In this work we have analyzed, by immunohistochemical and RT-qPCR analysis, the expression of L1CAM in a cohort of 113 endometrial cancers at different stages, which 50{\%} have relapsed. As a predictor of good outcome, the tumors were also analyzed for the expression of miR-34a, a post-transcriptional regulator of L1CAM. RESULTS: Among metastatic EC, the highest levels (60{\%}) and the median level (24{\%}) of L1CAM in tumors correlate with the progression, suggesting that the expression of this molecule is linked to the tumor component most involved in metastatic processes. We also found an inverse correlation between miR-34a and L1CAM protein expression, suggesting that miR-34a is a positive prognostic marker of EC. CONCLUSIONS: Our results demonstrate the expression of L1CAM and miR-34a in EC as prognostic factors that identify subgroup of patients at high risk of recurrence suggesting for them more aggressive schedules of treatment.",
keywords = "Endometrial cancer, Innovative biotechnology, L1CAM, Personalised approach, Prognostic biomarker",
author = "G. Corrado and V. Laquintana and R. Loria and M. Carosi and Salvo, {L. de} and I. Sperduti and A. Zampa and L. Cicchillitti and G. Piaggio and G. Cutillo and R. Falcioni and E. Vizza",
note = "LR: 20180710; JID: 8308647; OTO: NOTNLM; 2018/05/01 00:00 [received]; 2018/06/28 00:00 [accepted]; 2018/07/08 06:00 [entrez]; 2018/07/08 06:00 [pubmed]; 2018/07/08 06:00 [medline]; epublish",
year = "2018",
month = "7",
day = "6",
doi = "10.1186/s13046-018-0816-1 [doi]",
language = "English",
volume = "37",
pages = "139",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers

AU - Corrado, G.

AU - Laquintana, V.

AU - Loria, R.

AU - Carosi, M.

AU - Salvo, L. de

AU - Sperduti, I.

AU - Zampa, A.

AU - Cicchillitti, L.

AU - Piaggio, G.

AU - Cutillo, G.

AU - Falcioni, R.

AU - Vizza, E.

N1 - LR: 20180710; JID: 8308647; OTO: NOTNLM; 2018/05/01 00:00 [received]; 2018/06/28 00:00 [accepted]; 2018/07/08 06:00 [entrez]; 2018/07/08 06:00 [pubmed]; 2018/07/08 06:00 [medline]; epublish

PY - 2018/7/6

Y1 - 2018/7/6

N2 - BACKGROUND: Patients with endometrial cancer (EC) and presumably with good prognosis may develop a recurrence indicating that the classification of this tumor is still not definitive and that new markers are needed to identify a subgroup at risk of relapse. The cell adhesion molecule L1CAM is highly expressed in several human carcinomas and has recently been described as a new marker for endometrial and ovarian carcinomas. The aim of this study was to determine the relevance of L1CAM in recurrent EC. METHODS: In this work we have analyzed, by immunohistochemical and RT-qPCR analysis, the expression of L1CAM in a cohort of 113 endometrial cancers at different stages, which 50% have relapsed. As a predictor of good outcome, the tumors were also analyzed for the expression of miR-34a, a post-transcriptional regulator of L1CAM. RESULTS: Among metastatic EC, the highest levels (60%) and the median level (24%) of L1CAM in tumors correlate with the progression, suggesting that the expression of this molecule is linked to the tumor component most involved in metastatic processes. We also found an inverse correlation between miR-34a and L1CAM protein expression, suggesting that miR-34a is a positive prognostic marker of EC. CONCLUSIONS: Our results demonstrate the expression of L1CAM and miR-34a in EC as prognostic factors that identify subgroup of patients at high risk of recurrence suggesting for them more aggressive schedules of treatment.

AB - BACKGROUND: Patients with endometrial cancer (EC) and presumably with good prognosis may develop a recurrence indicating that the classification of this tumor is still not definitive and that new markers are needed to identify a subgroup at risk of relapse. The cell adhesion molecule L1CAM is highly expressed in several human carcinomas and has recently been described as a new marker for endometrial and ovarian carcinomas. The aim of this study was to determine the relevance of L1CAM in recurrent EC. METHODS: In this work we have analyzed, by immunohistochemical and RT-qPCR analysis, the expression of L1CAM in a cohort of 113 endometrial cancers at different stages, which 50% have relapsed. As a predictor of good outcome, the tumors were also analyzed for the expression of miR-34a, a post-transcriptional regulator of L1CAM. RESULTS: Among metastatic EC, the highest levels (60%) and the median level (24%) of L1CAM in tumors correlate with the progression, suggesting that the expression of this molecule is linked to the tumor component most involved in metastatic processes. We also found an inverse correlation between miR-34a and L1CAM protein expression, suggesting that miR-34a is a positive prognostic marker of EC. CONCLUSIONS: Our results demonstrate the expression of L1CAM and miR-34a in EC as prognostic factors that identify subgroup of patients at high risk of recurrence suggesting for them more aggressive schedules of treatment.

KW - Endometrial cancer

KW - Innovative biotechnology

KW - L1CAM

KW - Personalised approach

KW - Prognostic biomarker

U2 - 10.1186/s13046-018-0816-1 [doi]

DO - 10.1186/s13046-018-0816-1 [doi]

M3 - Article

VL - 37

SP - 139

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 1

ER -